rituximab,etoposide,futibatinib,cyclophosphamide,cisplatin
otsuka
[' futi', 'ritux', 'etoposide', 'cyclophosphamide', 'lymphoma', 'cisplatin', 'dlbcl']
dr. stewart on behalf of on saturday poster session in rr dlbcl fit for asct. 52% primary refractory (pr). median age 58. new regimen rdicep (1 cycle) vs. rgdp (3 cycles).orr (%) 65.6 vs48.6,pr 50 vs. 31.6, asct rate 72 vs. 54. stopped trial 4 toxicity. #ash22 
Happily married. Hematologist & Stem Cell Transplanter. field of interest: lymphoma-myeloma and chemoresistance biomarkers. @HematoClinicBCN @hematosantpau. EHS